Arcus and Gilead Announce Phase 3 TIGIT Program Failure in Upper GI Cancers

Arcus and Gilead have reported a significant setback in their clinical development, as the Phase 3 study of their anti-TIGIT antibody, domvanalimab, has failed to meet its primary endpoints in upper gastrointestinal cancers. The trial investigated the efficacy of domvanalimab in combination with an experimental anti-PD-1 agent and chemotherapy, but results indicate that the treatment did not provide the anticipated clinical benefit.

This failure adds to the growing list of challenges facing TIGIT-targeted therapies, which have struggled to demonstrate robust efficacy in various cancer indications. The implications for Arcus and Gilead are profound, as this setback may impact their strategic direction and investor confidence, potentially leading to a reevaluation of their oncology portfolio. As the competitive landscape in immuno-oncology continues to evolve, the industry will be closely watching how these companies respond to this disappointing outcome and what it means for future TIGIT research.